WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will report financial results for the second quarter ended June 30, 2009 on Wednesday, August 5, 2009, after the U.S. financial markets close.
